Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The autoimmune regulator protein (AIRE) is a transcription factor encoded by the AIRE gene on chromosome 21q22.3. It is primarily expressed in medullary thymic epithelial cells within the thymus, where it plays a critical role in establishing central immune tolerance. By promoting the expression of a wide array of tissue-restricted antigens within these cells, AIRE enables developing T cells to be exposed to self-antigens; those that react are eliminated through apoptosis—a process known as negative selection[1][2][4][5]. This mechanism prevents autoreactive T cells from entering circulation and causing autoimmune disease. AIRE also influences regulatory T cell development and may have additional roles outside the thymus, including possible functions in secondary lymphoid organs[2]. Deficiency or mutation in AIRE leads to breakdowns in immune tolerance, resulting most notably in autoimmune polyglandular syndrome type 1 (APS1/APECED), characterized by multiple endocrine failures and increased susceptibility to infections such as chronic mucocutaneous candidiasis[3][4][6]. While no drugs currently target AIRE directly for therapeutic purposes—making interacting_drugs and mechanism_of_action entries null—its function is central to understanding autoimmunity pathogenesis. Biomarkers related to its dysfunction include genetic testing for AIRE mutations and detection of certain autoantibodies seen with its deficiency. There are no specific safety concerns or therapeutic challenges directly associated with targeting this molecule at present due to lack of direct pharmacological interventions; however, manipulation could theoretically risk broad immunosuppression or loss of essential immune surveillance if not precisely controlled. In summary, autoimmune regulator protein is an essential nuclear transcription factor governing central immune tolerance by mediating deletion or regulation of self-reactive lymphocytes during their development[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autoimmune regulator protein (AIRE).